Theraclion to Host Key Opinion Leader Meeting and Webcast in New York on October 16, 2015

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that it will host a breast tumor-focused key opinion leader breakfast on Friday, October 16, 2015, from 8am-9:30am Eastern Time in New York City.

The meeting will feature keynote presentations by two breast tumor specialists, Dr. David Brenin and Dr. Kathie-Ann Joseph. Members of the Theraclion executive management team will also provide an overview of the Company's operations and products, including Echopulse® for the treatment of patients with breast fibroadenomas and benign thyroid nodules.

This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Mac MacDonald at 212-915-2567 or via e-mail at mac@lifesciadvisors.com. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20151016.

David Brenin, MD, FACS, is Chief of Breast Surgery, Co-Director of both the University of Virginia (UVA) Breast Care Program and the High-Risk Breast and Ovarian Cancer Clinic, and is an Associate Professor of Surgery at UVA’s School of Medicine.

Dr. Brenin’s clinical practice specializes in the treatment of breast cancer and benign diseases of the breast. He is a fellowship-trained breast surgeon and is an expert on surgical procedures involving the breast, including lumpectomy, sentinel node biopsy, axillary dissection, nipple sparing mastectomy and IORT. His primary research interests include focused ultrasound ablation of breast tumors and immunotherapy.

In addition to his clinical functions, Dr. Brenin is Chairman of the Commission on Cancer Committee at UVA Cancer Center, leader of UVA Cancer Center’s weekly multi-disciplinary breast conference and a member of the Focused Ultrasound Surgery Foundation’s Fellowship Advisory Committee and grant review committee.

Kathie-Ann Joseph, MD, MPH, FACS, is Chief of Breast Surgery at Bellevue Hospital at New York University (NYU) Langone Medical Center, where she is an Associate Professor of Surgery. She also chairs Bellevue's Breast Program Leadership Committee, which is a designated Center of Excellence in Breast Cancer.

Dr. Joseph specializes in the management and treatment of breast cancer. She has a keen research interest in health disparities in breast cancer treatment and is dedicated to improving access to screening in underserved populations and communities. She holds several grants for breast cancer research from such organizations as the American Cancer Society, the National Institutes of Health, the Breast Cancer Alliance, and Women at Risk.

A graduate of Harvard College and Columbia University College of Physicians and Surgeons, Dr. Joseph completed her general surgery residency at NYU Medical Center and her breast surgery fellowship at Columbia University.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20151013006402/en/